<p>(a) HepG-2 cells without Compound 1 treatment were used as control and (b, c) HepG-2 cells treated with Compound 1 (15 μM and 30 μM) for 24 h, respectively.</p
<p>(A) LX-2 cells were cultured with mock control, conditioned media from HepG2 (HepG2-CM), or condi...
<p>(A) 37°C treated cells for 3.75 hours and then fixed and imaged; (B) DAPI stained cells shown in ...
<p>a and b) HepG2 control cells. c and d) HepG2 cells treated with 25 µg/ml of CD-3. e and f) HepG2 ...
<p>a) control, b and c treated with 12.5 µM complexes <b>1</b> and <b>2</b>, respectively.</p
<p>(A) Untreated cells as control. (B) Treated with α-MMC for 48 h. (C) Treated with MAP30 for 48 h....
<p>HepG2 cells were treated in different sub-fractions and concentrations for 24 h, and then cell we...
<p>Nuclear morphology of HepG2 and SMMC7721 cells treated with 5, 10, and 20 µM abieslactone or 20 µ...
<p>A(a)-(c). The morphology changes of HepG2 cells treated with gradient H-EtOAc fraction for 24 h u...
<p>The nuclei morphological changes of HepG2 cell were observed with fluorescence microscopy after i...
<p>HepG2 cells (2.5×10<sup>4</sup>/mL) were incubated for 4 h to allow sufficient attachment. For th...
<p>Hoechst33342, TO-PRO-3, and TMRM were used to characterize the untreated HepG2 population and the...
<p>The cells were seeded with or without 1,3,4-thiadiazolium derivatives at 25 μM for 18–24 h. Then,...
<p>HepG2 cells were treated with 100 µM of fatty acid esters of phloridzin (Pz), pz or phloretin or ...
<p>(A) HepG2 cells were treated with medium alone and 12.5 µg/mL CF, HF, or BF, then stained with Ho...
<p>(A) HepG2 cells were cultured after 47°C heat treatment. The 24 h, 48 h and 72 h cell viability o...
<p>(A) LX-2 cells were cultured with mock control, conditioned media from HepG2 (HepG2-CM), or condi...
<p>(A) 37°C treated cells for 3.75 hours and then fixed and imaged; (B) DAPI stained cells shown in ...
<p>a and b) HepG2 control cells. c and d) HepG2 cells treated with 25 µg/ml of CD-3. e and f) HepG2 ...
<p>a) control, b and c treated with 12.5 µM complexes <b>1</b> and <b>2</b>, respectively.</p
<p>(A) Untreated cells as control. (B) Treated with α-MMC for 48 h. (C) Treated with MAP30 for 48 h....
<p>HepG2 cells were treated in different sub-fractions and concentrations for 24 h, and then cell we...
<p>Nuclear morphology of HepG2 and SMMC7721 cells treated with 5, 10, and 20 µM abieslactone or 20 µ...
<p>A(a)-(c). The morphology changes of HepG2 cells treated with gradient H-EtOAc fraction for 24 h u...
<p>The nuclei morphological changes of HepG2 cell were observed with fluorescence microscopy after i...
<p>HepG2 cells (2.5×10<sup>4</sup>/mL) were incubated for 4 h to allow sufficient attachment. For th...
<p>Hoechst33342, TO-PRO-3, and TMRM were used to characterize the untreated HepG2 population and the...
<p>The cells were seeded with or without 1,3,4-thiadiazolium derivatives at 25 μM for 18–24 h. Then,...
<p>HepG2 cells were treated with 100 µM of fatty acid esters of phloridzin (Pz), pz or phloretin or ...
<p>(A) HepG2 cells were treated with medium alone and 12.5 µg/mL CF, HF, or BF, then stained with Ho...
<p>(A) HepG2 cells were cultured after 47°C heat treatment. The 24 h, 48 h and 72 h cell viability o...
<p>(A) LX-2 cells were cultured with mock control, conditioned media from HepG2 (HepG2-CM), or condi...
<p>(A) 37°C treated cells for 3.75 hours and then fixed and imaged; (B) DAPI stained cells shown in ...
<p>a and b) HepG2 control cells. c and d) HepG2 cells treated with 25 µg/ml of CD-3. e and f) HepG2 ...
DOI
Add to ORKG